Q BioMed Inc’s technology partner Mannin Research Inc presents acute kidney injury treatment data at the American Society of Nephrology’s annual meeting in Washington DC


Q BioMed Inc's technology partner Mannin Research Inc presents acute kidney injury treatment data at the American Society of Nephrology’s annual meeting in Washington DC

Mannin’s data showed that the Ang-Tie2 signaling pathway represents a promising therapeutic target to treat AKI

() announced that its technology partner Mannin Research Inc highlighted a potential new treatment for acute kidney injury (AKI) at a medical conference in Washington DC earlier this month. 

Mannin’s data, presented at the American Society of Nephrology’s annual meeting, showed that the Ang-Tie2 signaling pathway represents a promising therapeutic target to treat AKI after hypotension, sepsis or cardiovascular events such as strokes. 

Those types of events can cause ischemia, or low blood flow. The sudden return of blood flow, known as ischemia–reperfusion, can cause AKI.

READ: Q BioMed’s manufacturer of cancer bone pain drug Strontium-89 wins FDA clearance; shares rocket

“We are very encouraged by this data,” Mannin CEO George Nikopoulos said in a statement. “Taken together with our recently announced funding and establishment of a research center in Saxony, Germany, this data will enable us to advance our program in developing therapeutics to treat acute kidney injury, bolstering our pipeline. We look forward to the day when we can make a difference in the lives of patients with kidney and cardiovascular diseases.”

The cost of hospitalizations for patients with complications from AKI can range between $5.4 and $24.0 billion in the US, Q BioMed said, so a potential treatment represents a major therapeutic opportunity.

Q BioMed has been partners with Mannin since 2015 and has an exclusive option on all Mannin portfolio assets.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel


Source link